Urticaria

This study follows 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) injections every two weeks. Researchers will monitor side effects and check if the drug helps control swelling attacks over 12 months. The goal is to see how well TAKHZYR…

This Phase 3 trial tests the long-term safety and effectiveness of navenibart, an injectable drug, in 145 adults and teens with hereditary angioedema (HAE) who were in a previous study. The trial has two parts: first, everyone gets a fixed dose; then, some may switch to a persona…

This study looks at the long-term safety and effectiveness of barzolvolimab in adults with chronic spontaneous urticaria (CSU), a condition causing frequent hives and itching. Participants have already completed earlier phase 3 trials. The goal is to see how well the drug control…

This phase 3 trial tests a one-time gene editing treatment called NTLA-2002 for people with hereditary angioedema (HAE), a rare genetic condition causing sudden, painful swelling attacks. About 80 participants will receive either the treatment or a placebo. The goal is to see if …

This early-stage study tests a new drug called cizutamig in about 20 adults with IgE-mediated allergies, including food allergies. The main goal is to see if the drug can safely lower IgE levels, which are antibodies that trigger allergic reactions. Researchers will also monitor …

This study tests an experimental drug called BLU-808 for people with chronic hives (urticaria) that don't get better with standard antihistamines. The drug works by blocking a protein called KIT, which may help control the allergic reaction causing the hives. About 105 adults wil…

This study tests a drug called remibrutinib in teenagers aged 12 to 17 who have chronic spontaneous urticaria (hives that come and go for no clear reason) that isn't controlled by antihistamines. About 100 participants will receive either the drug or a placebo for 24 weeks, with …

This Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…

This study tests a new drug called ADX-324 for hereditary angioedema (HAE), a rare genetic condition that causes sudden, severe swelling in the body. The trial has two parts: first, a small group of healthy volunteers will receive the drug to check its safety and how the body pro…

This study tests a new medication, remibrutinib, for people with chronic hives caused by triggers like cold, heat, or scratching (chronic inducible urticaria). The drug aims to control symptoms better than standard antihistamines. About 362 adults will take the drug or a placebo …

This study tests a new daily pill, remibrutinib, for adults with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control well. About 470 participants will receive either remibrutinib, a placebo, or an active control (omalizumab injections) fo…

This study tests a new drug (omalizumab α) against the approved drug Xolair for people with chronic hives that don't get better with antihistamines. About 392 adults aged 15 to 75 will receive either the new drug or Xolair to see how well it reduces itching and hives over 12 week…

This study tests an experimental drug called BW-20805 in 25 adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug can reduce how often attacks happen over about 6 months. Participants must have had at least 2 att…

This study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (CSU), a condition causing long-term hives and itching that doesn't get better with standard antihistamines. About 963 adults will receive either the drug or a placebo to see if it redu…

This study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene editing to lower a protein that triggers these attacks. The goal is to see if it is safe and can reduce h…

This phase 3 study tests barzolvolimab, a new biologic drug, in 976 adults with chronic spontaneous urticaria (CSU) whose hives and itching persist despite antihistamines. Participants receive either barzolvolimab or a placebo by injection. The main goal is to see if the drug red…

This study tests the long-term safety and effectiveness of remibrutinib, a daily pill, for adults with chronic spontaneous urticaria (hives). Participants who completed earlier phase 3 trials will either continue on the drug or switch to placebo to see if symptoms return. The goa…

This study tests a daily medication called berotralstat in 29 children aged 2 to under 12 who have hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The goal is to find the right dose based on weight and to check if it is safe and effective at…

This Phase 3 trial tests whether a once-daily pill called deucrictibant can prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants receive either the drug or a placebo for 24 weeks, and researchers count how many attacks occur. …

This study gives people with hereditary angioedema (HAE) who were in earlier berotralstat trials continued access to the medication. About 139 participants will receive berotralstat and be monitored for side effects. The goal is to keep treating their condition while gathering mo…

This early-stage trial tests a single dose of LP-003, a new drug for chronic spontaneous urticaria (long-lasting hives), in 12 healthy adults. The main goal is to check safety and how the body processes the drug. It is not yet tested in people with hives.

This study tests the long-term safety and effectiveness of donidalorsen, a drug given as a shot under the skin, to prevent attacks of hereditary angioedema (HAE). HAE causes sudden, painful swelling in various body parts. The trial involves 154 participants who previously complet…

This study follows about 100 people with hereditary angioedema who previously received the gene-editing therapy NTLA-2002. Researchers will monitor side effects and how well the treatment controls swelling attacks over time. The goal is to understand if a single dose can provide …

This study tests a pill called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have had HAE attacks before will take the drug as needed and be monitored for safety and…

This trial investigates whether a low-histamine and pseudoallergen-free diet can reduce symptoms like hives and itching in children aged 1 to 18 with chronic spontaneous urticaria. Participants follow the diet for 4 weeks while continuing standard care. Researchers track changes …

This study tests a new drug called TLL-018 in 440 adults with moderate-to-severe chronic hives (chronic spontaneous urticaria) that aren't controlled by standard antihistamines. Participants receive either TLL-018 or a placebo for 12 weeks to see if it reduces itching and hives b…

This study tested whether ritlecitinib, a drug already approved for another condition, could safely reduce hives and itching in people with chronic spontaneous urticaria (CSU). The trial planned to enroll adults aged 18–65 who have had hives for over six weeks. Participants would…

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study looks at how diet and oxidative stress (an imbalance of harmful molecules in the body) relate to chronic spontaneous urticaria (CSU), a condition causing itchy hives and swelling. Researchers will compare adults with active CSU to healthy volunteers, tracking their die…

This study aimed to learn more about the unpredictable swelling attacks in people with bradykinin-mediated angioedema, a rare condition that can cause life-threatening airway swelling. Participants would have used a smartphone app daily to report attacks and possible triggers. Th…

This study follows 50 people in the UK with hereditary angioedema (HAE) types I or II who are taking lanadelumab. Researchers will compare the number of HAE attacks in the year before starting the drug to up to two years after. The goal is to see how well the drug works outside o…